Meeting
2023 ASCO Gastrointestinal Cancers Symposium
Nivolumab and a CCR2/CCR5 dual antagonist (BMS-813160) with or without GVAX for locally advanced pancreatic ductal adenocarcinomas: Results of phase I study.
Authors
Eric Christenson
Sidney Kimmel Cancer Center, Johns Hopkins University, Baltimore, MD;
Eric Christenson , Su Jin Lim , Hao Wang , Anna Ferguson , Rose Parkinson , Yvette Cetasaan , Christina Rodriguez , Richard Burkhart , Ana De Jesus-Acosta , Jin He , Rachel B. Klein , Kelly Lafaro , Dan Laheru , Dung T. Le , Christopher Shubert , Neeha Zaidi , Elizabeth M. Jaffee , William Burns , Amol Narang , Lei Zheng
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT03767582
Citation
J Clin Oncol 41, 2023 (suppl 4; abstr 730)
DOI
10.1200/JCO.2023.41.4_suppl.730
Abstract #
730
Poster Bd #
L17
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Gastrointestinal Cancers Symposium
A multicenter, randomized phase II study of total neoadjuvant therapy (TNT) with FOLFIRINOX (FFX) and SBRT, with or without losartan (L) and nivolumab (N) in borderline resectable (BR) and locally advanced (LA) pancreatic ductal adenocarcinoma (PDAC).
First Author: Theodore S. Hong
Poster
2024 ASCO Gastrointestinal Cancers Symposium
KRAS mutation status in the prediction of pancreatic tumor response after neoadjuvant systemic therapy and magnetic resonance-guided SBRT.
First Author: Amit Jethanandani
Poster
2023 ASCO Gastrointestinal Cancers Symposium
A phase II study of durvalumab and stereotactic ablative body radiotherapy (SABR) in locally advanced pancreatic adenocarcinoma (LA PDAC).
First Author: Fergus Keane
Poster
2022 ASCO Gastrointestinal Cancers Symposium
NeoOPTIMIZE: An open-label, phase II trial and biomarker discovery platform to assess the efficacy of adaptive switching of modified FOLFIRINOX (mFFX) or gemcitabine/nab-paclitaxel (GA) as a neoadjuvant strategy for patients with resectable/borderline resectable and locally advanced unresectable pancreatic ductal adenocarcinoma (PDAC).
First Author: Charles D. Lopez